Abstract
Alzheimer’s disease (AD) is a progressive multifactorial neurodegenerative disorder. Currently, no effective treatment is available and this is due to multiple factors involved in pathophysiology and severity of AD. A recent approach for the rational design of new drug candidates, also called multitarget-directed ligands (MTDL) strategy, has been used to develop a variety of hybrid compounds capable to act simultaneously in diverse biological targets. The discovery of drug candidates capable of targeting multiple factors involved in AD pathogenesis would greatly facilitate in improving therapeutic strategies. This review is a complement to another review article, recently published by our group, which covered the previous period of 2005-2012, and highlights recent advances and examples of the exploitation of MTDLs approach in the rational design of novel drug candidate prototypes for the treatment of AD.
Keywords: Alzheimer`s disease, multi-target directed drugs, rational drug design, multifunctional drugs, multitarget drugs, neurodegenerative diseases, MTDLs.
Current Medicinal Chemistry
Title:Multi-Target Directed Drugs as a Modern Approach for Drug Design Towards Alzheimer’s Disease: An Update
Volume: 25 Issue: 29
Author(s): Matheus de Freitas Silva, Kris Simone Tranches Dias, Vanessa Silva Gontijo, Cindy Juliet Cristancho Ortiz and Claudio Viegas Jr.*
Affiliation:
- PeQuiM - Laboratory of Research in Medicinal Chemistry, Institute of Chemistry, Federal University of Alfenas, 37133-840,Brazil
Keywords: Alzheimer`s disease, multi-target directed drugs, rational drug design, multifunctional drugs, multitarget drugs, neurodegenerative diseases, MTDLs.
Abstract: Alzheimer’s disease (AD) is a progressive multifactorial neurodegenerative disorder. Currently, no effective treatment is available and this is due to multiple factors involved in pathophysiology and severity of AD. A recent approach for the rational design of new drug candidates, also called multitarget-directed ligands (MTDL) strategy, has been used to develop a variety of hybrid compounds capable to act simultaneously in diverse biological targets. The discovery of drug candidates capable of targeting multiple factors involved in AD pathogenesis would greatly facilitate in improving therapeutic strategies. This review is a complement to another review article, recently published by our group, which covered the previous period of 2005-2012, and highlights recent advances and examples of the exploitation of MTDLs approach in the rational design of novel drug candidate prototypes for the treatment of AD.
Export Options
About this article
Cite this article as:
de Freitas Silva Matheus, Dias Simone Tranches Kris, Gontijo Silva Vanessa, Ortiz Juliet Cristancho Cindy and Viegas Jr. Claudio*, Multi-Target Directed Drugs as a Modern Approach for Drug Design Towards Alzheimer’s Disease: An Update, Current Medicinal Chemistry 2018; 25 (29) . https://dx.doi.org/10.2174/0929867325666180111101843
DOI https://dx.doi.org/10.2174/0929867325666180111101843 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Toll-like Receptors as a Novel Therapeutic Target for Natural Products Against Chronic Diseases
Current Drug Targets The Pharmacokinetics and Toxicology of Aluminum in the Brain
Current Inorganic Chemistry (Discontinued) Cholinergic System Dysfunction and Neurodegenerative Diseases: Cause or Effect?
CNS & Neurological Disorders - Drug Targets Regulation and Quantification of Cellular Mitochondrial Morphology and Content
Current Pharmaceutical Design Recent Patents and Discovery of Anti-inflammatory Agents from Marine Source
Recent Patents on Inflammation & Allergy Drug Discovery Cysteine Protease Inhibitors: from Evolutionary Relationships to Modern Chemotherapeutic Design for the Treatment of Infectious Diseases
Current Protein & Peptide Science Utilizing Ultrasound to Transiently Increase Blood-Brain Barrier Permeability, Modulate of the Tight Junction Proteins, and Alter Cytoskeletal Structure
Current Neurovascular Research Homocysteine Level and Mechanisms of Injury in Parkinson's Disease as Related to MTHFR, MTR, and MTHFD1 Genes Polymorphisms and LDopa Treatment
Current Genomics Neurogenesis and Alzheimers Disease: Biology and Pathophysiology in Mice and Men
Current Alzheimer Research Meet Our Editorial Board Member:
Protein & Peptide Letters The Cannabinoid CB2 Receptor as a Target for Inflammation-Dependent Neurodegeneration
Current Neuropharmacology SUBJECT INDEX TO VOLUME 1
Current Genomics Small Molecule Approaches for Promoting Neurogenesis
Current Alzheimer Research Computer Aided Drug Design and its Application to the Development of Potential Drugs for Neurodegenerative Disorders
Current Neuropharmacology The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Potential Drugs and Methods for Preventing or Delaying the Progression of Huntington's Disease
Recent Patents on CNS Drug Discovery (Discontinued) Microfluidic Methods for Non-Viral Gene Delivery
Current Gene Therapy Nicotinic Receptors Containing the α7 Subunit: A Model for Rational Drug Design
Current Medicinal Chemistry Metformin: A Growing Journey from Glycemic Control to the Treatment of Alzheimer’s Disease and Depression
Current Medicinal Chemistry The Unbiased Search of Biomarkers in Neurodegenerative Diseases
Current Pharmaceutical Biotechnology